Abstract Treatment options for patients with metastatic melanoma, and especially BRAF-
mutant melanoma, have changed dramatically in the past 5 years, with the FDA approval of …

The discovery of the role of the RAS/RAF/MEK/ERK pathway in melanomagenesis and its
progression have opened a new era in the treatment of this tumor. Vemurafenib was the first …

Growth factor receptors rank among the most important oncogenic pathways, but
pharmacologic inhibitors often demonstrate limited benefit as monotherapy. Here, we show …

Background: Melanoma is highly immunogenic and therefore suitable for immunotherapy,
but the efficacy is limited by response rate. In several types of tumor, tumor mutation burden …

Tumor-associated macrophages (TAMs) are major component of leukocytic infiltrate of
tumors and play important roles in progression and regression of tumors. Tumor …

New drugs introduced to the market every year represent privileged structures for particular
biological targets. These new chemical entities (NCEs) provide insight into molecular …

Purpose: Mitogen-activates protein kinase (MAPK) inhibitors, particularly MEK inhibitors,
have shifted the treatment paradigm for metastatic BRAF-mutant cutaneous melanoma; …

Melanoma remains mostly an untreatable fatal disease despite advances in decoding
cancer genomics and developing new therapeutic modalities. Progress in patient care …

Approaches to reduce the global burden of cancer include two major strategies: screening
and early detection and active preventive intervention. The latter is the topic of this …

Melanoma is the deadliest form of skin cancer. While associated survival prognosis is good
when diagnosed early, it dramatically drops when melanoma progresses into its metastatic …